Welcome to our dedicated page for iTeos Therapeutics news (Ticker: ITOS), a resource for investors and traders seeking the latest updates and insights on iTeos Therapeutics stock.
iTeos Therapeutics, Inc. (NASDAQ: ITOS) is a clinical-stage biopharmaceutical company committed to enhancing the lives of cancer patients through innovative immunotherapies. Founded in 2012 and headquartered in Gosselies, Belgium, with a research center in Watertown, Massachusetts, iTeos leverages deep insights into tumor immunology and immunosuppressive pathways to design novel product candidates.
The company's pipeline includes several promising drug candidates:
- EOS-200271: A potent and selective IDO1 inhibitor with exceptional brain penetration, currently in clinical stages.
- EOS-100850 (Inupadenant): An insurmountable adenosine A2A receptor antagonist designed to inhibit the ATP-adenosine pathway. This therapeutic candidate is in Phase 2 studies, targeting high adenosine concentrations in solid tumors.
- EOS-884448 (Belrestotug): An anti-TIGIT antibody developed to enhance the anti-tumor immune response. This candidate is being progressed in multiple indications in collaboration with GSK and is currently in Phase 1 trials.
- EOS-984: A first-in-class small molecule aimed at inhibiting the immunosuppressive activity of adenosine. This candidate is in Phase 1 development, with studies showing potential synergy with Inupadenant.
iTeos is supported by the Ludwig Institute for Cancer Research, the Walloon Region of Belgium, and the European Fund for Economic and Regional Development (FEDER). Notably, the company has secured a partnership with GSK to develop the TIGIT:PD-1 doublet therapy, which has the potential to become a leading treatment in the immuno-oncology field.
For the latest updates and detailed information, visit the 'Investors' section of their website at www.iteostherapeutics.com.
iTeos Therapeutics (NASDAQ: ITOS) announced a collaboration with GSK for the co-development of EOS-448, receiving a $625 million upfront payment and potential milestone payments of $1.45 billion. The agreement includes a 40/60 cost-sharing on global development and a 50/50 profit sharing in the U.S. Initial clinical data presented shows promising anti-cancer activity for EOS-448. The company reported a cash balance of $302.9 million as of June 30, 2021, bolstered by the GSK payment, extending its runway into 2026.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) will host a conference call on August 12, 2021, at 8:00 a.m. ET to report its second quarter 2021 financial results and offer a corporate update. The event will be accessible via a pre-registration link and a live audio webcast available on the company's investor relations website. iTeos is focused on immuno-oncology therapeutics with ongoing trials for EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist. Preliminary data indicates potential clinical activity and favorable tolerability for both candidates.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) has announced the presentation of its CEO, Michel Detheux, at the Wedbush PacGrow Healthcare Conference on August 10, 2021, at 2:20 p.m. ET. The conference will feature a live webcast available on the company’s website, with an archived replay accessible for 30 days.
iTeos focuses on developing innovative immuno-oncology therapeutics, including two promising clinical-stage programs. Their lead candidate, EOS-448, targets anti-TIGIT mechanisms, showing preliminary clinical activity, while inupadenant aims to combat cancer immunosuppression.
iTeos Therapeutics (Nasdaq: ITOS), a clinical-stage biopharmaceutical firm, will have its CEO Michel Detheux, PhD, participate in a panel at the William Blair Biotech Focus Conference 2021 on July 14, 2021, at 2:10 p.m. ET. The discussion will revolve around developing therapies for new immuno-oncology targets. A live webcast of the event will be available on the company’s website, with an archived replay accessible for 30 days post-event. iTeos focuses on innovative immuno-oncology therapeutics, with clinical programs such as EOS-448 and inupadenant showing promising early results.
iTeos Therapeutics (ITOS) and GlaxoSmithKline (GSK) have announced a collaboration to co-develop EOS-448, an anti-TIGIT monoclonal antibody, currently in phase I for advanced solid tumors. Under this agreement, iTeos will receive a $625 million upfront payment, with potential milestone payments totaling up to $1.45 billion. GSK will co-commercialize EOS-448 in the US, sharing profits, while receiving exclusive commercialization rights outside the US, along with tiered royalties. The partnership aims to enhance immuno-oncology therapies targeting the CD226 axis.
iTeos Therapeutics (NASDAQ: ITOS) announced positive results from its Phase 1/2a trial of inupadenant (EOS-850), an A2AR antagonist, at ASCO 2021. Out of 43 patients, five showed durable responses or stable disease for over six months, including noteworthy results in melanoma and non-small cell lung cancer cases. Preliminary analyses suggest that A2AR expression correlates with clinical outcomes. The monotherapy was well-tolerated, with serious adverse events not indicating new safety concerns. iTeos plans further trials combining inupadenant with pembrolizumab and chemotherapy.
iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Michel Detheux will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 8:00 a.m. ET. A live webcast will be available on the company's website, with an archived replay for 30 days. iTeos focuses on developing innovative immuno-oncology therapeutics, including EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist. Both candidates are undergoing clinical trials showcasing preliminary clinical activity in adult patients with advanced solid tumors.
iTeos Therapeutics (NASDAQ: ITOS) reported its Q1 2021 financial results, highlighting a cash balance of $321.4 million to support ongoing clinical advancements. The company is progressing in its development of two lead programs, EOS-448 and inupadenant, with significant clinical data expected before the end of 2022. EOS-448 showed promising initial results in its Phase 1 trial, while inupadenant's updated data will be presented at the upcoming ASCO Annual Meeting. R&D expenses increased to $11.6 million, reflecting heightened clinical activity.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) will host a conference call and live webcast on May 13, 2021, at 4:30 p.m. ET to discuss its first quarter 2021 financial results and provide a corporate update. The company focuses on developing immuno-oncology therapeutics, with key programs including EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist. Both candidates are currently undergoing clinical trials to evaluate their effectiveness in treating advanced solid tumors.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) has appointed Dr. Tony Ho and Dr. Robert Iannone to its Board of Directors, enhancing the company's expertise in clinical drug development. CEO David Hallal emphasized their vast experience in driving oncology products through clinical phases, which will be crucial as iTeos progresses its EOS-448 and inupadenant programs. Both appointees have significant backgrounds in the pharmaceutical industry, which may accelerate iTeos' immuno-oncology pipeline aimed at improving cancer treatment outcomes.
FAQ
What is the current stock price of iTeos Therapeutics (ITOS)?
What is the market cap of iTeos Therapeutics (ITOS)?
What does iTeos Therapeutics, Inc. do?
What are the key products in iTeos' pipeline?
Where is iTeos Therapeutics headquartered?
What is EOS-200271?
What is Inupadenant (EOS-100850)?
Who are iTeos' key partners?
What is EOS-884448 (Belrestotug)?
What is EOS-984?
Where can I find the latest news about iTeos Therapeutics?
